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Abstract
Erythema multiforme (EM) is an acute, immune-mediated condition which affects the skin and mucous membranes.
EM is a type 4 hypersensitivity reaction typically mediated by cytotoxic T lymphocytes. It is usually a self limiting,
transient, inﬂammatory disease that spontaneously resolves within weeks without major sequelae. However, occasionally patients might have frequent recurrences, persistent disease or serious complications like ﬂuid and electrolyte
abnormalities. The most common triggers are infection followed by medications. Here we present the case of an 81-yearold female who came in with worsening lip and tongue swelling associated with a rash and was diagnosed with EM
major due to naproxen.
Keywords: Erythema multiforme major, Erythema multiforme minor, Non-steroidal antiinﬂammatory drug, Herpes
simplex virus, Naproxen

1. Introduction
he term erythema multiforme (EM) was ﬁrst
coined by Ferdinand von Hebra in 1860.1 Erythema multiforme is a self limiting, acute, immune
mediated, inﬂammatory mucocutaneous disorder
characterized by distinctive target-like skin eruptions with or without oral mucous membrane lesions.1,2 The main differentiating features between
erythema multiforme major (EMM) and erythema
multiforme minor(EMm) is mucous membrane
involvement and associated systemic symptoms like
fever and arthralgias which is seen in EMM.1,2 A
variety of factors have been implicated in the pathogenesis of EM. Most common inciting factors are
infection, mainly herpes simplex virus, and medications.1,2 Here we are presenting a case of EMM
due to naproxen.

T

2. Case presentation
An 81-year-old female with a history of hypertension on lisinopril for many years presented with
progressive lip swelling and a rash for 3 days. The

rash had started suddenly; initially it was made up
of small, rounded, vesicular lesions on her extremities, most notably on her palms and soles, which
evolved into targetoid lesions. She also complained
of lip swelling and skin peeling. She denied fever,
ﬂu-like symptoms, urinary symptoms, joint pain,
myalgias, changes in her bowel habit, as well as
recent changes in diet, body products or her living
environment. She denied a history of similar episodes in the past. She was allergic to sulfonamides,
lisinopril and iodinated contrast media.Upon
further questioning, she had been having back pain
for a week, for which he had been taking naproxen.
At the time of presentation she was afebrile, had a
heart rate 80 beats/min, and a blood pressure of 143/
80 mm Hg. On physical examination she had a
bilateral and symmetrical rash made up of welldeﬁned, rounded, target-like lesions on affecting the
distal segments of her extremities, mainly the palms
and soles; some of these lesions had developed superﬁcial ulceration and crusting in the center surrounded by three zones of erythematous halos. She
also had superﬁcial ulcerations and desquamation
of her lips. No bullae were noted (Figs. 1e3). She
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At a 6-month follow up she had complete resolution
of the lesions without recurrence.

3. Discussion

Fig. 1. Target like lesions in the soles.

was started on oral prednisone 40 mg once daily and
antihistamines as needed for itching. Barrier lip and
skin ointment were used for symptomatic management of her lesions. A skin biopsy from one of the
lesions in the extremities showed necrotic keratinocytes (Fig. 4). ANA was negative which ruled out
systemic lupus erythematosus (SLE), SLE can be
associated with EM-like lesions. Non-steroidal
antiinﬂammatory drugs (NSAID) were added to the
allergy list and she was advised to avoid NSAID for
life. Her lesions improved rapidly with treatment
and she was discharged after 4 days on a tapering
course of oral prednisone for two additional weeks.

Fig. 2. Target like lesions in the palms, some of them with double halos.

EM is an acute, typically self limited mucocutaneous inﬂammatory and hypersensitivity reaction
characterized by a distinctive target like skin eruption with or without oral or other mucous membrane involvement.1 It has been classiﬁed as EMM
or EMm based on the degree of mucosal involvement and extent of lesions.1 In EMM there is severe
mucosal involvement and may have associated
systemic symptoms such as fever and arthralgias;
however EMm refers to EM without or with only
mild mucosal disease and associated systemic
symptoms.1,2 In the past EM was on the different
spectrum of disease such as a Stevens-Johnson
syndrome (SJS) and toxic epidermal necrolysis
(TEN); however, now it is recognised as a distinct
clinical entity.1
The annual incidence is unknown due to the fact
that minor forms are not reported and does not
required hospitalization, it is estimated to be far less
than 1 percent.1e3 It has a predilection for young
adults between the ages of 20 and 40 years.3,4 EMM
is more frequently seen in females while EMm has
slight male predominance.1,3 No racial predominance has been noted based on our literature
review.1e3 EM can also occur in children and older
adults.3
EM is caused by a cell-mediated immune mechanism,1,3 This type of immune mediated reaction is
seen with a variety of antigens; among these infectious agents account for 90% of cases, Herpes simplex virus (HSV) 1 is the most common followed by
Mycoplasma pneumoniae especially in children.1,2
HSV 2 is also sometimes associated with EM.1,2

Fig. 3. Demonstrating a lip ulceration.

Fig. 4. H&E stain, high power ﬁeld, demonstrating necrotic keratinocytes (black arrow).

Many conditions have been implicated in the
pathogenesis of including a variety of viral and
bacterial infections, drugs, malignancies, autoimmune diseases, radiation, immunizations, pregnancy, menstruation, chemicals and food products.2
Less than 10% of cases are associated with medications3; however, based on some of the literature it
can be up to 50%.3 Medications that have been
commonly identiﬁed as causes of EM include
NSAID, sulfa drugs, anticonvulsants, tyrosine kinase inhibitors, biologic agents such as a tumor
necrosis factor alpha inhibitors, phosphoinositide 3kinase inhibitors and retinoids.2,3 EM has also been
associated with autoimmune diseases like inﬂammatory bowel disease, hematological malignancies
like leukemia and lymphoma and some solid malignancies like renal cell carcinoma and gastric
adenocarcinoma.2 Vaccines such as measles,
mumps and rubella, hepatitis B and pneumococcal
vaccines have also been linked to EM.2
Increased disease susceptibility with HLA associated alleles has also been reported, especially HLA
DQ3 is associated with recurrent EM.5 The main
chemokine found in drug-associated EM is tumor
necrosis factor alpha while interferon gamma is
more commonly found in HSV associated EM.2,5
HSV genes are expressed on antigen expressing
keratinocytes which in turns recruit T helper cells
and release interferon gamma which in turn leads to
subepithelial and intraepithelial vesiculation
complicated by extensive blistering and erosions.1,5
Lesions develop 10e14 days after the initial HSV
infection and usually resolve within 2 weeks.3 Some
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lesions can persist for up to 5 weeks.2 The term
multiforme describes a myriad of clinical manifestations. EM most often manifests with combined
cutaneous and mucosal features; sometimes only
cutaneous or mucosal lesions can be seen.5 Typical
three component target or iris lesions are the hallmark of EM however it these are not always present.2,5 Oral involvement is seen in 70% cases.1,3,4
The most commonly affected sites are the vermilion
border of lip and the buccal, labial and lingual
mucosal surfaces.1,3 The appearance of the rash can
make it difﬁcult to distinguish from other vesiculobullous lesions.4 The skin lesions in EMm are
usually symmetrical typical targetoid lesions in extremities.4 The lesions in EMM are more atypical
and often palpable.4 Sometimes it can involve the
eyes and lacrimation and photophobia can be the
initial presentation.1 Prodromal symptoms are uncommon in mild cases and but can be seen when
there is signiﬁcant mucosal involvement.2,5
The history and physical examination are essential for diagnosis of EM, if needed skin biopsy helps
to conﬁrm diagnosis.1,2 Histopathology sometimes
helps to rule out other diseases like lupus erythematosus or vasculitis.2 Biopsy results depend on the
site of biopsy and the timing of the lesion.2 Characteristic pathological ﬁndings include necrotic
keratinocytes, spongiosis, focal vacuolar degeneration of basal keratinocytes and as the inﬂammatory
reaction evolves, perivascular inﬂammatory inﬁltrate and exocytosis.4,5 No speciﬁc laboratory abnormalities have been identiﬁed except in very
severe cases of EM where there can be elevated
levels of erythrocyte sedimentation rate, white
blood cells and liver enzymes.1,5
Our differential diagnosis included a wide range
drug induced mucocutaneous eruptions like SJS,
urticaria, ﬁxed drug eruption, SLE, bullous pemphigoid and hypersensitivity reactions.2 SJS usually
presents with widespread atypical targetoid lesions
and macules; more severe with worse systemic
involvement and manifestations as compared to
EM.5 Urticaria lesions usually disappears within
24 h as compared to ﬁxed lesions of EM.2,5 Itching is
more pronounced in urticaria.5 Fixed drug eruption
is a hypersensitivity reactions to speciﬁc drugs with
fewer lesions usually occurs within 8 h of re-exposure to the culprit drug.2 The mainstay of treatment
is to stop the suspected triggering agent.1,5 No
speciﬁc treatment has been identiﬁed.1,6 Most mild
cases can be managed symptomatically as an
outpatient or might required topical corticosteroids.1,6,7 Severe forms causing ﬂuid and electrolyte
imbalances require hospitalization, intravenous
ﬂuids and standard systemic corticosteroids, for
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example prednisone at a dose of 0.5e1 mg/kg/
day.1,6 Immunosuppressants like cyclosporine,
azathioprine, cyclophosphamide and thalidomide
are sometimes used alone or in combination with
steroids.1,3e5 Antiviral therapy is reserved for
recurrent EM.2,3
Based on our literature review only one case of
naproxen induced erythema multiforme has been
reported in a 4 year old girl who had a history of
carbamazepine induced SLE and developed EM.
There are few case reports linking different NSAIDs
like diclofenac, celecoxib and piroxicam to Erythema Multiforme also reported.

4. Conclusion
This case highlights the importance of considering
medication side effects in differential diagnosis of
acute rashes as their discontinuation is a key part of
treatment. EM in elderly patients, speciﬁcally,
should prompt detailed history-taking to ﬁnd the
possible triggering agent and stop the culprit drug

to avoid future more severe presentations and/or
sequelae.
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